Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ENOV

ENOV - Enovis Corporation Stock Price, Fair Value and News

$21.45-0.53 (-2.41%)
Market Closed

55/100

ENOV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

55/100

ENOV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$24.51

Target 3M

$23.38

Target 6M

$23.75

ENOV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENOV Price Action

Last 7 days

-9.4%

Last 30 days

-20.8%

Last 90 days

-30.1%

Trailing 12 Months

-55.0%

ENOV RSI Chart

ENOV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENOV Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

0.55

EV/EBITDA

-2.54

Price/Free Cashflow

53.89

ENOV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$24.51

Target 3M

$23.38

Target 6M

$23.75

ENOV Fundamentals

ENOV Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

8.65%

Rev. Growth (Qtr)

-2.77%

ENOV Earnings

Earnings (TTM)

-1.4B

Earnings Growth (Yr)

-1.7K%

Earnings Growth (Qtr)

-1.5K%

ENOV Profitability

EBT Margin

-59.27%

Return on Equity

-67.64%

Return on Assets

-30.83%

Free Cashflow Yield

1.86%

ENOV Investor Care

Shares Dilution (1Y)

2.35%

Diluted EPS (TTM)

-24.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.2B2.2B2.2B0
20241.8B1.9B2.0B2.1B
20231.6B1.6B1.7B1.7B
20221.5B1.5B1.6B1.6B
20212.6B2.3B1.9B1.4B
20203.5B3.2B3.1B3.1B
20192.3B2.7B3.0B3.3B
20183.1B2.8B2.5B2.2B
20173.2B3.2B3.2B3.3B
20163.8B3.6B3.4B3.2B
20154.5B4.3B4.1B4.0B
20144.3B4.4B4.6B4.6B
20134.0B4.0B4.1B4.2B
20121.4B2.3B3.1B3.9B
2011580.6M644.4M682.3M693.4M
2010000542.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Enovis Corporation

ENOV
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
 CEO
 WEBSITEenovis.com
 SECTORIndustrials
 INDUSTRYSpecialty Industrial Machinery
 EMPLOYEES6800

Enovis Corporation Frequently Asked Questions

ENOV is the stock ticker symbol of Enovis Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Enovis Corporation is 1.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ENOV's fair value in chart for subscribers.

The fair value guage provides a quick view whether ENOV is over valued or under valued. Whether Enovis Corporation is cheap or expensive depends on the assumptions which impact Enovis Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENOV.

As of Wed Jan 28 2026, ENOV's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENOV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Enovis Corporation has provided -0.056 (multiply by 100 for percentage) rate of return.